Evidence map›Paper›PMID 40758882›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Protective antigen-mediated delivery of an anti-CRISPR protein for precision genome editing.

Axel O Vera, Nicholas L Truex, Vedagopuram Sreekanth, Bradley L Pentelute, Amit Choudhary, Ronald T Raines

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Axel O VeraDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0003-4522-2793
Nicholas L TruexDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139.
Vedagopuram SreekanthChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, MA 02141.
Bradley L PenteluteDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139.
Amit ChoudharyChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, MA 02141.
Ronald T RainesDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0001-7164-1719

Funding

Protein ChemistryR35GM148220 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Ronald T Raines · 2023 to 2026
$2.2M
Chemical approaches for precision genome editingR01GM137606 · NIGMS · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT · 2021 to 2024
$1.5M
Opera Phenix high-throughput microplate confocal imager for high-content screeningS10OD026839 · OD · BROAD INSTITUTE, INC. · PI WAGNER, BRIDGET K · 2019 to 2019
$1.0M
Cytosolic Delivery of Tumor Antigens into Dendritic CellsF32CA239362 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TRUEX, NICHOLAS L · 2020 to 2022
$179k
Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome EditingF31GM148042 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VERA, AXEL O · 2022 to 2023
$69k
NCI NIH HHS F32 CA239362NIGMS NIH HHS F31 GM148042NIGMS NIH HHS R01 GM137606NIGMS NIH HHS R35 GM148220NIH HHS S10 OD026839
6 · The paper itself

Abstract

Precise control over the dosage of Cas9-based technologies is essential because off-target effects, mosaicism, chromosomal aberrations, immunogenicity, and genotoxicity can arise with prolonged Cas9 activity. Type II anti-CRISPR proteins (Acrs) inhibit and control Cas9 but are generally impermeable to the cell membrane due to their size and anionic charge. Moreover, existing Acr delivery methods are long-lived and operate within hours (e.g., viral and nonviral vectors) or require external devices (e.g., electroporation), limiting therapeutic applications. To address these problems, we developed a protein-based anti-CRISPR delivery platform, LF

Indexed as

Antigens, BacterialBacterial ToxinsCRISPR-Cas SystemsGene EditingCRISPR-Associated Protein 9HEK293 CellsHumansanthrax toxinAntigens, BacterialBacterial ToxinsCRISPR-Associated Protein 9anthrax protective antigenanti-CRISPRCRISPR-Cas9precision genome editingprotein delivery

Identifiers

PMID40758882
PMCPMC12358904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.